GE HealthCare stock heads into the open after a modest gain
Published on 09/15/2026 at 07:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GE HealthCare stock closed at USD 64.23 on the Nasdaq on September 14, 2026, up 0.47 percent from the prior session per exchange data cited in recent market coverage. The move left the shares modestly ahead of a softer S&P 500, which fell 0.5 percent to 7,619.98 on the same day.
September 14, 2026 in numbers
GE HealthCare Technologies Inc. (ISIN US36266G1076, Nasdaq: GEHC) saw its Nasdaq session on September 14, 2026 end at USD 64.23, with the closing level fitting within the day range reported around that price point and marking a small gain versus the previous close. Per data referenced by MarketBeat, the quote reflected regular trading hours and a session change of 0.47 percent, while MarketScreener noted a recent closing level of USD 63.93 earlier in the week, underscoring that Monday’s finish represented a slight recovery within the current band of trading around the mid-60s USD.
Sector chatter also provided context for the stock. MarketBeat highlighted that the average analyst price target compiled in its overview stood at USD 82.50 for GE HealthCare, implying a notable gap from the latest close that continues to frame the shares’ medium-term performance expectations. The broader backdrop was more cautious: the S&P 500 slipped 0.5 percent to 7,619.98 on September 14, 2026 as major United States indexes eased according to a wrap from Barchart, meaning GE HealthCare’s small advance came against a mildly declining market.
Deal talks shape today’s focus
Today’s attention on GE HealthCare is shaped primarily by ongoing reports that the company is in discussions over a roughly USD 1 billion acquisition of Sofie Biosciences, a maker of cancer scan chemicals and radiopharmaceuticals used in imaging. As Crains Chicago Business reported on September 14, 2026, the potential deal value is around USD 1 billion, adding a strategic corporate action angle for investors to weigh ahead of the open. A separate headline-only update from Benzinga on September 14, 2026 echoed the framing that GE HealthCare is in talks over a USD 1 billion deal for a maker of cancer scan chemicals, reinforcing the sense that possible inorganic expansion in imaging agents is a near-term narrative driver.
With no earnings release or shareholder meeting scheduled for today in the visible calendars, investors heading into the open are likely to continue parsing the implications of the Sofie Biosciences discussions for GE HealthCare’s portfolio and capital allocation, while also watching how the shares trade relative to the broader health care space after slightly outperforming the S&P 500 in the last completed session.
